These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12477073)

  • 1. A decision theoretic approach to sample size determination in clinical trials.
    Gittins JC; Pezeshk H
    J Biopharm Stat; 2002 Nov; 12(4):535-51. PubMed ID: 12477073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
    Kikuchi T; Gittins J
    Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The choice of sample size: a mixed Bayesian / frequentist approach.
    Pezeshk H; Nematollahi N; Maroufy V; Gittins J
    Stat Methods Med Res; 2009 Apr; 18(2):183-94. PubMed ID: 18445695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety.
    Kikuchi T; Gittins J
    Stat Med; 2009 Aug; 28(18):2293-306. PubMed ID: 19536745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian sample size calculation for estimation of the difference between two binomial proportions.
    Pezeshk H; Nematollahi N; Maroufy V; Marriott P; Gittins J
    Stat Methods Med Res; 2013 Dec; 22(6):598-611. PubMed ID: 21436190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal choice of the number of treatments to be included in a clinical trial.
    Stallard N; Posch M; Friede T; Koenig F; Brannath W
    Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance and sample size requirements of Bayesian methods for binary outcomes in fixed-dose combination drug studies.
    Holt MM; Stamey JD; Seaman JW; Young DM
    J Biopharm Stat; 2009; 19(1):120-32. PubMed ID: 19127471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of information and optimal clinical trial design.
    Willan AR; Pinto EM
    Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian techniques for sample size determination in clinical trials: a short review.
    Pezeshk H
    Stat Methods Med Res; 2003 Dec; 12(6):489-504. PubMed ID: 14653352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust Bayesian sample size determination in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2008 Jun; 27(13):2290-306. PubMed ID: 18205170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach.
    Berry DA; Ho CH
    Biometrics; 1988 Mar; 44(1):219-27. PubMed ID: 3358990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian sample size for exploratory clinical trials incorporating historical data.
    Whitehead J; Valdés-Márquez E; Johnson P; Graham G
    Stat Med; 2008 Jun; 27(13):2307-27. PubMed ID: 18069728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approximately optimal designs for phase II clinical studies.
    Stallard N
    J Biopharm Stat; 1998 Jul; 8(3):469-87. PubMed ID: 9741860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
    Patel NR; Ankolekar S
    Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.